Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2024-03-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度会计师事务所履职情况评估报告" which translates to "2023 Annual Evaluation Report on the Performance of the Accounting Firm." It details the qualifications, independence, quality control, and audit procedures of the accounting firm (立信会计师事务所) that audited the company 百奥泰生物制药股份有限公司. The content focuses on the audit firm's performance and compliance with relevant laws and standards during the 2023 audit. It is not the full annual report or audit report itself but an evaluation of the audit firm's work and quality management. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report discussing audit quality and procedures, not the full annual report or financial statements. The document length is 3227 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, the best classification is AR with high confidence.
2024-03-28 Chinese
百奥泰 2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed information about the company's business, products, industry overview, and financial data for the year 2023. The length is substantial (15,000 characters), indicating it is a full report or a detailed summary rather than a brief announcement. It includes management discussion, risk factors, product pipeline, industry analysis, and financial data, all typical components of an Annual Report. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2024-03-28 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金及部分自有资金进行现金管理的核查意见
Regulatory Filings
2024-03-28 Chinese
百奥泰 第二届监事会第十三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board (监事会) of 百奥泰生物制药股份有限公司 during their 13th meeting of the 2nd term. It includes approvals of the 2023 Annual Report, Supervisory Board Work Report, Internal Control Evaluation Report, Financial Statements, Profit Distribution Plan, and other governance and financial matters. The document repeatedly states that these reports and announcements are published separately on the Shanghai Stock Exchange website and media on March 29, 2024. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's resolutions regarding these reports and plans, which will be submitted to the shareholders' meeting for approval. The document length is about 4916 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of Supervisory Board meeting resolutions and related approvals, not the full Annual Report or financial statements themselves.
2024-03-28 Chinese
百奥泰 2023年度独立董事述职报告-黄德汉
Regulatory Filings
2024-03-28 Chinese
百奥泰 关于使用部分暂时闲置募集资金及部分自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the use of temporarily idle raised funds and some of its own funds for cash management. It details the board meeting approval, investment purpose, investment products, amounts, risk control measures, and opinions from the audit committee, supervisory board, and sponsor institution. The document does not contain financial statements or detailed financial results but is a regulatory disclosure about the company's financing fund management activities. It is not an annual or interim report, earnings release, or audit report. It is a formal announcement about capital/financing activities related to the use of raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive content, so it is not a mere report publication announcement or regulatory filing fallback.
2024-03-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.